BEAT

What one share of HeartBeam holds

Surgical and Medical Instruments and Apparatus

HeartBeam is a medical technology company focused on transforming cardiac care through the power of personalized insights. Our aim is to deliver innovative, higher resolution ambulatory cardiac monitoring solutions that can be used by patients anywhere to enable the detection and monitoring of cardiac disease outside of a healthcare facility.

HeartBeam’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.

Per-share figures
Profit−$0.50
Capex (buildings and equipment)$0.02
Free cash flow−$0.34
Cash and investments$0.15
Book value$0.15

Per share by fiscal year

YearSalesProfitCapexFree cashDividendsBook value
2020—−$0.29———−$1.36
2021—−$1.03———$1.72
2022—−$1.59$0.00−$1.22—$0.30
2023—−$0.72$0.01−$0.61—$0.61
2024—−$0.73$0.01−$0.55—$0.06
2025—−$0.62$0.02−$0.43—$0.10

Common questions about HeartBeam

How much does one share of HeartBeam earn?

Over the last 12 months, HeartBeam lost $0.50 for each share.

Does HeartBeam pay a dividend?

HeartBeam didn’t pay a dividend over the last 12 months, according to its SEC filings.

What is HeartBeam’s book value per share?

HeartBeam’s book value is $0.15 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of June 30, 2026.

How much cash and debt does each share of HeartBeam have?

Each share of HeartBeam has $0.15 of cash and investments, as of June 30, 2026.

What is HeartBeam’s free cash flow per share?

−$0.34 per share over the last 12 months. Free cash flow is the cash left over after spending on buildings and equipment.

Has HeartBeam bought back shares?

HeartBeam’s share count rose about 825% from 2020 to 2025. That dilution means each share owns a smaller slice of the company.

From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.